Produced by the Royal College of Physicians of Edinburgh and Royal College of Physicians and Surgeons of Glasgow

References

  1. Walsh SJ, Algert C, Rothfield NF. Racial aspects of comorbidity in systemic lupus erythematosus. Arthritis Care Res 1996; 9(6):509–16.
  2. McCarty DJ, Manzi S, Medsger TA Jr et al. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 1995; 38(9):1260–70.
  3. Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis 1994; 53(10):675–80.
  4. Nightingale AL, Farmer RDT, de Vries, CS. Incidence of clinically diagnosed systemic lupus erythematosus 1992–1998 using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15(9):656–61.
  5. Naleway AL, Davis ME, Greenlee RT et al. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus 2005; 14(10):862–6.
  6. Govoni M, Castellino G, Bosi S et al. Incidence and prevalence of systemic lupus erythematosus in a district of north Italy. Lupus 2006; 15(2):110–3.
  7. Huang CM, Yang YH, Chiang BL. Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis. J Microbiol Immunol Infect 2004; 37(2):88–94.
  8. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271–7.
  9. D’Cruz DP. Systemic lupus Erythematosis. BMJ 2006; 332:890–4.
  10. Spano’ A, Loi G, De Luca B et al. Long-term iloprost therapy of severe Raynaud’s phenomenon in connective tissue diseases. Arthritis Rheum 2001; 44(S9):S330.
  11. Boumpas DT, Sidropoulos P, Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat Clin Pract Rheumatol 2005; 1(1):22–30.
  12. Sofat N, Malik O, Higgens CS. Neurological involvement in patients with rheumatic disease. QJM 2006; 99(2):69–79.
  13. Merrill JT, Asherson RA. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol 2006; 2(2):81–9.
  14. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2006; 25(9):1776–85.
  15. Bruce IN. ‘Not only… but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatol 2005; 44(12):1492–1502.